Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.
ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...
News Nation on MSN
Patrick Soon-Shiong’s cancer drug approved by Saudi FDA
Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...
By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.
InvestorsHub on MSN
Theralase and Ferring ink deal for new bladder cancer study
Theralase Technologies (USOTC:TLTFF) signed a clinical development agreement with Ferring Pharmaceuticals, a top name in ...
GlobalData on MSN
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Detailed price information for Biovaxys Technology Corp (BVAXF) from The Globe and Mail including charting and trades.
Ferring Pharmaceuticals and Theralase ® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback